| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Dominique Endres, Lena Jelinek, Katharina Domschke, Ulrich Voderholze. [Treatment-resistant obsessive-compulsive disorders]. Der Nervenarzt. 2024-03-11. PMID:38466350. |
obsessive-compulsive disorders (ocd) are mainly treated with disorder-specific cognitive behavioral therapy using exposure and response management and/or selective serotonin reuptake inhibitors; however, a significant subgroup of patients does not sufficiently benefit from this approach. |
2024-03-11 |
2024-03-14 |
Not clear |
| Paula A Gajeswski-Kurdziel, Allison E Walsh, Randy D Blakel. Functional and pathological consequences of being fast on the uptake: Protein kinase G and p38α MAPK regulation of serotonin transporters. Current research in physiology. vol 7. 2024-02-01. PMID:38298474. |
serotonin (5-hydroxytryptamine, 5-ht) signaling plays an important role in dynamic control of peripheral and central nervous system physiology, with altered 5-ht homeostasis implicated in a significant number of disorders, ranging from pulmonary, bowel, and metabolic disease to depression, obsessive-compulsive disorder, and autism spectrum disorder (asd). |
2024-02-01 |
2024-02-03 |
Not clear |
| Matti Cervin, Joseph F McGuire, Johann M D'Souza, Alessandro S De Nadai, Kristina Aspvall, Wayne K Goodman, Per Andrén, Sophie C Schneider, Daniel A Geller, David Mataix-Cols, Eric A Storc. Efficacy and acceptability of cognitive-behavioral therapy and serotonin reuptake inhibitors for pediatric obsessive-compulsive disorder: a network meta-analysis. Journal of child psychology and psychiatry, and allied disciplines. 2024-01-03. PMID:38171647. |
efficacy and acceptability of cognitive-behavioral therapy and serotonin reuptake inhibitors for pediatric obsessive-compulsive disorder: a network meta-analysis. |
2024-01-03 |
2024-01-06 |
Not clear |
| Matti Cervin, Joseph F McGuire, Johann M D'Souza, Alessandro S De Nadai, Kristina Aspvall, Wayne K Goodman, Per Andrén, Sophie C Schneider, Daniel A Geller, David Mataix-Cols, Eric A Storc. Efficacy and acceptability of cognitive-behavioral therapy and serotonin reuptake inhibitors for pediatric obsessive-compulsive disorder: a network meta-analysis. Journal of child psychology and psychiatry, and allied disciplines. 2024-01-03. PMID:38171647. |
cognitive-behavioral therapy (cbt) and serotonin reuptake inhibitors (sris) are recommended treatments for pediatric obsessive-compulsive disorder (ocd), but their relative efficacy and acceptability have not been comprehensively examined. |
2024-01-03 |
2024-01-06 |
Not clear |
| Jianzhao Zhang, Hui Zhong, Yiliang Zhang, Jie Yin, Xiaodong Song, Kaiwei Ye, Zijin Song, Shunkai Lai, Shuming Zhong, Zhen Wang, Yanbin Ji. Personality traits as predictors for treatment response to sertraline among unmedicated obsessive-compulsive Disorder: A 12-weeks retrospective longitudinal study. Journal of psychiatric research. vol 170. 2024-01-03. PMID:38171218. |
the effectiveness of selective serotonin reuptake inhibitors (ssris) as a primary treatment for obsessive-compulsive disorder (ocd) remains uncertain. |
2024-01-03 |
2024-01-06 |
Not clear |
| Jeremy Tyler, Thea Gallagher, Michael G Wheaton, Gabriella E Hamlett, Ben Rosenfield, David Rosenfield, Helen B Simpson, Edna B Fo. Predictors of clinical worsening during a discontinuation trial of serotonin reuptake inhibitors for obsessive compulsive disorder. Journal of anxiety disorders. vol 101. 2023-12-19. PMID:38113781. |
predictors of clinical worsening during a discontinuation trial of serotonin reuptake inhibitors for obsessive compulsive disorder. |
2023-12-19 |
2023-12-23 |
Not clear |
| Jeremy Tyler, Thea Gallagher, Michael G Wheaton, Gabriella E Hamlett, Ben Rosenfield, David Rosenfield, Helen B Simpson, Edna B Fo. Predictors of clinical worsening during a discontinuation trial of serotonin reuptake inhibitors for obsessive compulsive disorder. Journal of anxiety disorders. vol 101. 2023-12-19. PMID:38113781. |
to explore predictors and moderators of clinical worsening during a double-blind trial in which patients with obsessive-compulsive disorder (ocd) were randomized to either continue or discontinue their serotonin reuptake inhibitor (sri) medication after achieving wellness from the addition of exposure and response prevention (ex/rp) therapy. |
2023-12-19 |
2023-12-23 |
Not clear |
| Negin Eissazade, Hesam Mosavari, Shayan Eghdami, Mahsa Boroon, Faria Ashrafi, Mohammadreza Shalbafa. Efficacy and safety of 5-hydroxytryptamine-3 (5-HT3) receptor antagonists in augmentation with selective serotonin reuptake inhibitors (SSRIs) in the treatment of moderate to severe obsessive-compulsive disorder: a systematic review and meta-analysis of randomized clinical trials. Scientific reports. vol 13. issue 1. 2023-11-27. PMID:38012263. |
efficacy and safety of 5-hydroxytryptamine-3 (5-ht3) receptor antagonists in augmentation with selective serotonin reuptake inhibitors (ssris) in the treatment of moderate to severe obsessive-compulsive disorder: a systematic review and meta-analysis of randomized clinical trials. |
2023-11-27 |
2023-11-29 |
Not clear |
| Negin Eissazade, Hesam Mosavari, Shayan Eghdami, Mahsa Boroon, Faria Ashrafi, Mohammadreza Shalbafa. Efficacy and safety of 5-hydroxytryptamine-3 (5-HT3) receptor antagonists in augmentation with selective serotonin reuptake inhibitors (SSRIs) in the treatment of moderate to severe obsessive-compulsive disorder: a systematic review and meta-analysis of randomized clinical trials. Scientific reports. vol 13. issue 1. 2023-11-27. PMID:38012263. |
obsessive-compulsive disorder (ocd) is the fourth most common mental disorder, and selective serotonin reuptake inhibitors (ssris) are the cornerstone of its pharmacological treatment. |
2023-11-27 |
2023-11-29 |
Not clear |
| Sheldon H Preskorn, Ryan Rod. Personalized Medicine in the Treatment of a Patient With Obsessive-Compulsive Disorder With Clomipramine. Journal of psychiatric practice. vol 29. issue 6. 2023-11-10. PMID:37948171. |
clomipramine (cimi) is an effective treatment for obsessive-compulsive disorder in patients who have failed to respond to trials of selective serotonin transport inhibitors (eg, sertraline). |
2023-11-10 |
2023-11-20 |
Not clear |
| Sheldon H Preskorn, Ryan Rod. Personalized Medicine in the Treatment of a Patient With Obsessive-Compulsive Disorder With Clomipramine. Journal of psychiatric practice. vol 29. issue 6. 2023-11-10. PMID:37948171. |
that conversion impairs the ability to inhibit the serotonin transporter, the mechanism that is most likely responsible for the efficacy of cimi in obsessive-compulsive disorder. |
2023-11-10 |
2023-11-20 |
Not clear |
| Shun Hamanaka, Taro Kishi, Kenji Sakuma, Yasufumi Nishii, Masakazu Hatano, Nakao Iwat. Serotonin 3 receptor antagonists for obsessive-compulsive disorder: A systematic review and pairwise meta-analysis. Journal of psychiatric research. vol 167. 2023-10-22. PMID:37866327. |
serotonin 3 receptor antagonists for obsessive-compulsive disorder: a systematic review and pairwise meta-analysis. |
2023-10-22 |
2023-11-08 |
Not clear |
| Shun Hamanaka, Taro Kishi, Kenji Sakuma, Yasufumi Nishii, Masakazu Hatano, Nakao Iwat. Serotonin 3 receptor antagonists for obsessive-compulsive disorder: A systematic review and pairwise meta-analysis. Journal of psychiatric research. vol 167. 2023-10-22. PMID:37866327. |
the benefits of serotonin 3 receptor antagonists (5-ht3r-as) in obsessive-compulsive disorder (ocd) treatment remain unclear. |
2023-10-22 |
2023-11-08 |
Not clear |
| Eun Hyun Seo, Seung-Gon Kim, Jae-Hon Lee, Hyung-Jun Yoo. Successful Early Lamotrigine and Aripiprazole Augmentation of Clomipramine in Severe Obsessive-compulsive Disorder. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology. vol 21. issue 3. 2023-07-10. PMID:37424428. |
lamotrigine and aripiprazole have shown efficacy as augmentation agents of serotonin reuptake inhibitors for treatment-resistant obsessive-compulsive disorder (ocd). |
2023-07-10 |
2023-08-14 |
Not clear |
| Eric M Mendez, Katherine K Dahlsgaard, John M Hjelmgren, Jeffrey A Mills, Vikram Suresh, Jeffrey R Straw. What Is the Added Benefit of Combining Cognitive Behavioral Therapy and Selective Serotonin Reuptake Inhibitors in Youth with Obsessive Compulsive Disorder? A Bayesian Hierarchical Modeling Meta-Analysis. Journal of child and adolescent psychopharmacology. 2023-06-22. PMID:37347947. |
what is the added benefit of combining cognitive behavioral therapy and selective serotonin reuptake inhibitors in youth with obsessive compulsive disorder? |
2023-06-22 |
2023-08-14 |
Not clear |
| Mohan Gauta. Clinical Recommendations for Augmentation Agents in Obsessive-Compulsive Disorder Partially Responsive to Serotonin Reuptake Inhibitors. Journal of clinical psychopharmacology. 2023-06-19. PMID:37335203. |
clinical recommendations for augmentation agents in obsessive-compulsive disorder partially responsive to serotonin reuptake inhibitors. |
2023-06-19 |
2023-08-14 |
Not clear |
| Rituparna Maiti, Archana Mishra, Anand Srinivasan, Biswa Ranjan Mishr. Pharmacological augmentation of serotonin reuptake inhibitors in patients with obsessive-compulsive disorder: A network meta-analysis. Acta psychiatrica Scandinavica. 2023-05-13. PMID:37177823. |
pharmacological augmentation of serotonin reuptake inhibitors in patients with obsessive-compulsive disorder: a network meta-analysis. |
2023-05-13 |
2023-08-14 |
Not clear |
| Rituparna Maiti, Archana Mishra, Anand Srinivasan, Biswa Ranjan Mishr. Pharmacological augmentation of serotonin reuptake inhibitors in patients with obsessive-compulsive disorder: A network meta-analysis. Acta psychiatrica Scandinavica. 2023-05-13. PMID:37177823. |
the augmentation of serotonin reuptake inhibitors (sris) can be achieved by add-on therapy with different pharmacological agents in obsessive-compulsive disorder (ocd) for a better clinical outcome. |
2023-05-13 |
2023-08-14 |
Not clear |
| Ramin Hamidi Farahani, Ali Ajam, Alireza Ranjbar Naein. Effect of fluvoxamine on preventing neuropsychiatric symptoms of post COVID syndrome in mild to moderate patients, a randomized placebo-controlled double-blind clinical trial. BMC infectious diseases. vol 23. issue 1. 2023-04-02. PMID:37003990. |
fluvoxamine, a selective serotonin reuptake inhibitor (ssri) that is mostly used to treat depression, anxiety disorders, and obsessive-compulsive disorder, has been suggested as an anti-covid drug due to its anti-inflammatory effects, mainly through the sigma-1 receptor. |
2023-04-02 |
2023-08-14 |
Not clear |
| Bruce J Kirenga, Levicatus Mugenyi, Marina Sánchez-Rico, Henry Kyobe, Winters Muttamba, Raymond Mugume, Eliya Mwesigwa, Ezra Kalimo, Vicky Nyombi, Ivan Segawa, Loryndah Olive Namakula, Rogers Sekibira, Wilberforce Kabweru, Rosemary Byanyima, Hellen Aanyu, Pauline Byakika-Kibwika, Henry G Mwebesa, Nicolas Hoertel, William Bazey. Association of fluvoxamine with mortality and symptom resolution among inpatients with COVID-19 in Uganda: a prospective interventional open-label cohort study. Molecular psychiatry. 2023-03-03. PMID:36869228. |
prior research suggests that fluvoxamine, a selective serotonin reuptake inhibitor (ssri) used for the treatment of obsessive-compulsive disorder and major depressive disorder, could be repurposed against covid-19. |
2023-03-03 |
2023-08-14 |
Not clear |